DV
Dividend Vision

LENZ — LENZ Therapeutics Inc

LENZ Therapeutics Inc (LENZ)

Its deepest 1-year drawdown was 90.6%.

LENZ Therapeutics is a commercial pharmaceutical company focused on developing and commercializing therapies to improve vision, with product candidates including VIZZ and LNZ101 for treating presbyopia in adults. The company does not currently distribute dividends. LENZ Therapeutics appeals primarily to growth-oriented investors seeking exposure to the ophthalmology and therapeutic development sector rather than income-focused investors.

LENZ key facts

Asset type
Stock
Asset class
Equity
Inception date
06/25/2021
Last close
$4.73
Market cap
$155,517,792
Average volume
701800.0
Ex-dividend date
03/22/2024
Beta
1.621
Payout ratio
0.0
Forward P/E
0.0
EPS
$-3.48